These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15163180)

  • 41. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.
    Wagner S; Breyholz HJ; Höltke C; Faust A; Schober O; Schäfers M; Kopka K
    Appl Radiat Isot; 2009 Apr; 67(4):606-10. PubMed ID: 19167232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
    Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
    J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
    Jani M; Tordai H; Trexler M; Bányai L; Patthy L
    Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.
    Kopka K; Breyholz HJ; Wagner S; Law MP; Riemann B; Schröer S; Trub M; Guilbert B; Levkau B; Schober O; Schäfers M
    Nucl Med Biol; 2004 Feb; 31(2):257-67. PubMed ID: 15013492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.
    Kohno T; Hochigai H; Yamashita E; Tsukihara T; Kanaoka M
    Biochem Biophys Res Commun; 2006 May; 344(1):315-22. PubMed ID: 16603129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
    Oltenfreiter R; Staelens L; Hillaert U; Heremans A; Noël A; Frankenne F; Slegers G
    Appl Radiat Isot; 2005 Jun; 62(6):903-13. PubMed ID: 15799868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structural basis for the highly selective inhibition of MMP-13.
    Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
    Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
    Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process.
    Amano S; Ogura Y; Akutsu N; Matsunaga Y; Kadoya K; Adachi E; Nishiyama T
    Br J Dermatol; 2005 Dec; 153 Suppl 2():37-46. PubMed ID: 16280020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.
    Szardenings AK; Harris D; Lam S; Shi L; Tien D; Wang Y; Patel DV; Navre M; Campbell DA
    J Med Chem; 1998 Jun; 41(13):2194-200. PubMed ID: 9632351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.
    Rowsell S; Hawtin P; Minshull CA; Jepson H; Brockbank SM; Barratt DG; Slater AM; McPheat WL; Waterson D; Henney AM; Pauptit RA
    J Mol Biol; 2002 May; 319(1):173-81. PubMed ID: 12051944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.
    Subramaniam R; Haldar MK; Tobwala S; Ganguly B; Srivastava DK; Mallik S
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3333-7. PubMed ID: 18442906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.
    Zapico JM; Serra P; García-Sanmartín J; Filipiak K; Carbajo RJ; Schott AK; Pineda-Lucena A; Martínez A; Martín-Santamaría S; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2011 Jun; 9(12):4587-99. PubMed ID: 21552627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.
    Sasanelli R; Boccarelli A; Giordano D; Laforgia M; Arnesano F; Natile G; Cardellicchio C; Capozzi MA; Coluccia M
    J Med Chem; 2007 Jul; 50(15):3434-41. PubMed ID: 17583333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid assembly of matrix metalloprotease inhibitors using click chemistry.
    Wang J; Uttamchandani M; Li J; Hu M; Yao SQ
    Org Lett; 2006 Aug; 8(17):3821-4. PubMed ID: 16898826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.
    Blagg JA; Noe MC; Wolf-Gouveia LA; Reiter LA; Laird ER; Chang SP; Danley DE; Downs JT; Elliott NC; Eskra JD; Griffiths RJ; Hardink JR; Haugeto AI; Jones CS; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robinson RP; Subramanyam C; Vaughn-Bowser ML; Yocum SA
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1807-10. PubMed ID: 15780611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
    Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J
    J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.
    Groneberg RD; Burns CJ; Morrissette MM; Ullrich JW; Morris RL; Darnbrough S; Djuric SW; Condon SM; McGeehan GM; Labaudiniere R; Neuenschwander K; Scotese AC; Kline JA
    J Med Chem; 1999 Feb; 42(4):541-4. PubMed ID: 10052961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.